天然产物研究与开发 ›› 2026, Vol. 38 ›› Issue (2): 403-411.doi: 10.16333/j.1001-6880.2026.2.017 cstr: 32307.14.1001-6880.2026.2.017

• 数据研究 • 上一篇    下一篇

基于网络药理学与体外实验探讨川芎对胶质母细胞瘤的作用机制

张  婷1*,李  娜1,朱  婷1,宋小锋1,王聪聪2   

  1. 1豫北医学院,新乡 453000;2江苏恒瑞医药股份有限公司,连云港 222000
  • 出版日期:2026-02-26 发布日期:2026-02-25
  • 基金资助:
    国家自然科学基金(82072802);河南省生物与医药重点学科资助项目(ZDXKXM013)

Mechanism of Ligusticum chuanxiong in glioblastoma based on network pharmacology and in vitro experiment

ZHANG Ting1*,LI Na1,ZHU Ting1,SONG Xiao-feng1,WANG Cong-cong2   

  1. 1North Henan Medical University,Xinxiang 453000,China;2Jiangsu Hengrui Medicine Co.,Ltd.,Lianyungang 222000,China
  • Online:2026-02-26 Published:2026-02-25

摘要:

采用网络药理学与体外细胞实验探究川芎(Ligusticum chuanxiong)治疗胶质母细胞瘤(glioblastoma,GBM)的作用机制。使用TCMSP 、DrugBank、DisGeNET、GeneCards、OMIM等数据库,预测川芎活性成分的作用靶点并获得GBM的疾病相关靶点,两者交集即为川芎抗GBM的作用靶点。采用DAVID v2021q4进行GO功能注释和KEGG通路富集分析。利用STRING 11.0平台和Cytoscape 3.8.2软件,构建潜在靶点蛋白-蛋白互作网络,并筛选核心靶点,对其亲和力进行分子对接验证。CCK-8法和Transwell实验检测川芎提取物对GBM细胞U251活力与侵袭能力的影响,RT-qPCR和Western blot验证川芎提取物对相关靶点基因与蛋白表达的影响。网络药理学分析出川芎抗GBM的潜在靶点69个,并筛选出5个核心靶点,主要涉及细胞增殖凋亡相关通路、癌症相关通路及代谢相关通路。分子对接显示核心靶点与川芎活性成分洋川芎醌、亚油酸乙酯、谷甾醇亲和力较好。体外细胞实验显示,与对照组相比,川芎提取物能明显降低U251细胞活力(P <0.05),抑制其侵袭,同时升高半胱天冬酶3(cysteinyl aspartate specific proteinase 3,Caspase-3)的mRNA及蛋白表达量,降低信号转导及转录激活因子3(signal transducer and activator of transcription 3,STAT3)与表皮生长因子受体(epidermal growth factor receptor,EGFR)mRNA和蛋白表达(P <0.05)。综上,川芎通过影响 Caspase-3、STAT3、EGFR等核心靶点,共同干预细胞增殖凋亡相关通路、癌症相关通路及代谢相关通路等,以达到抗GBM的作用。

关键词: 川芎, 胶质母细胞瘤, 网络药理学, 分子对接

Abstract:

This study aims to explore the mechanism of Ligusticum chuanxiong in the treatment of glioblastoma (GBM) by network pharmacology and in vitro cell experiments. The TCMSP, DrugBank, DisGeNET, GeneCards and OMIM databases were used to predict the active components and target genes of L. chuanxiong, as well as to obtain disease-related targets of GBM. The intersection of these targets was identified as the potential targets of L. chuanxiong against GBM. GO functional annotation and KEGG pathway enrichment analysis were performed using DAVID v2021q4. The STRING 11.0 platform and Cytoscape 3.8.2 software were used to construct a protein-protein interaction network of potential targets, screen core targets and validate their binding affinity through molecular docking. The effects of L. chuanxiong extract on the proliferation and invasion of U251 cells were detected using the CCK-8 assay and Transwell. Quantitative real-time polymerase chain reaction (RT-qPCR) and Western blot were used to verify the effects of L. chuanxiong extract on the expression of related target genes and proteins. Network pharmacology analysis identified 69 potential targets of L. chuanxiong against GBM and five core targets were screened out. These targets were mainly involved in pathways related to cell proliferation and apoptosis, cancer-related pathways and metabolic pathways. Molecular docking showed the core targets had good binding affinity with active components of L. chuanxiong, such as senkyunolide, ethyllinoleate and sitosterol. In vitro cell experiments showed that, compared with the control group, L. chuanxiong extract significantly reduced the viability of U251 cells (P<0.05), inhibited their invasion, increased the mRNA and protein expression of cysteinyl  aspartate specific proteinase 3 (Caspase-3),  decreased the mRNA and protein expression of signal transducer and activator of transcription 3 (STAT3) and epidermal growth factor receptor (EGFR) (P<0.05). In summary, L. chuanxiong exerts anti-GBM effects by influencing core targets such as Caspase-3, STAT3 and EGFR, thereby regulating pathways related to cell proliferation and apoptosis, cancer-related pathways and metabolic pathways.

Key words: Ligusticum chuanxiong, glioblastoma, network pharmacology, molecular docking

中图分类号:  R285.5